l-asparaginase resistance in human leukemia--asparagine synthetase.
about
Crystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding siteCrystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapyAsparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cellsComparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.Polysialic acids: potential role in therapeutic constructs.Asparagine-requiring tumor cell lines and their non-requiring variants: cytogenetics, biochemistry and population dynamics.Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity.Asparagine plays a critical role in regulating cellular adaptation to glutamine depletionAn inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line.A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.Clinical analysis and prognostic significance of L-asparaginase containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma.Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitisUse of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study.First-line treatment of acute lymphoblastic leukemia with pegasparaginase.Erwinia asparaginase in pediatric acute lymphoblastic leukemia.Cancer cell metabolism: one hallmark, many faces.Targeting the latest hallmark of cancer: another attempt at 'magic bullet' drugs targeting cancers' metabolic phenotype.Drug-induced amino acid deprivation as strategy for cancer therapy.Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell linesComparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlin-Frankfurt-Münster-based induction therapy for childhood acute lymphoblastic leukemia.Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response
P2860
Q27694569-A6908284-A3F1-4605-8A6E-07ADFE7B322EQ27732092-ABAEC1E6-F522-4055-A14F-D2824ACD00B5Q28367265-2CF0A72B-D37C-4B38-8423-09A39D38475AQ30457370-9906423D-B7FF-45BC-A220-DED990E8AB1DQ33718822-79351424-2F9E-4504-811D-94023578C00FQ33923401-346E7D89-64E2-4976-BBC2-7FB6A7C6C73FQ33989251-7FC53609-2C46-49D2-9584-51E6427F9FC8Q34400003-17C43886-9D22-4F1F-A868-184F1A03EDC5Q34473984-3F5C8543-78EC-457A-A408-D9FE0014B5BAQ34653242-8E73A7E9-A296-48E0-8685-E8F2D2CA507CQ34989475-0E285B22-7DD9-438C-A240-4916CE87F04CQ35677647-43BF2786-2395-45D4-A32B-C48B316AE9DCQ35958818-47C3F3A5-3559-4367-9CDD-547E4EBDB93BQ37291435-B67C3470-C0BF-4EBD-AEAF-6BA1A42A1A9AQ37522294-71F2748B-5F93-4934-9188-95E7FE48C5BAQ37586935-D5313760-392B-4517-A167-F8BB65304267Q38040418-16B88F96-641E-461A-BAF6-8FD3883D54B6Q38046274-B42E5AFD-0243-474E-9A70-9DCDA7ABF69FQ38058130-520E561C-1E72-40B8-BBD6-EAD0C35FA49DQ38657061-E53D9EA9-50A7-4FFC-BF07-20E8E2FBA0ACQ38915906-714FED30-FED7-46E3-BC1D-285144FE8F18Q38941947-CBAA0546-42E4-49CC-9D2A-F825B7AC6ACDQ38994917-F9DD41AF-1AA2-494E-9DF9-DD55105B986DQ39194553-CAF8A4E8-6AA4-46DE-9DF9-830352935A52Q48166631-AC667E54-A514-4BDB-974D-12ACAF836C57Q50791897-A42529AA-E670-4671-8758-7B4FBCDEBB89Q57998597-DBA57ABF-F4AA-4130-993C-2F5080BC5F67
P2860
l-asparaginase resistance in human leukemia--asparagine synthetase.
description
1969 nî lūn-bûn
@nan
1969 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1969 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1969年の論文
@ja
1969年論文
@yue
1969年論文
@zh-hant
1969年論文
@zh-hk
1969年論文
@zh-mo
1969年論文
@zh-tw
1969年论文
@wuu
name
l-asparaginase resistance in human leukemia--asparagine synthetase.
@ast
l-asparaginase resistance in human leukemia--asparagine synthetase.
@en
l-asparaginase resistance in human leukemia--asparagine synthetase.
@nl
type
label
l-asparaginase resistance in human leukemia--asparagine synthetase.
@ast
l-asparaginase resistance in human leukemia--asparagine synthetase.
@en
l-asparaginase resistance in human leukemia--asparagine synthetase.
@nl
prefLabel
l-asparaginase resistance in human leukemia--asparagine synthetase.
@ast
l-asparaginase resistance in human leukemia--asparagine synthetase.
@en
l-asparaginase resistance in human leukemia--asparagine synthetase.
@nl
P1476
l-asparaginase resistance in human leukemia--asparagine synthetase.
@en
P2093
Canellos GP
Haskell CM
P304
P356
10.1016/0006-2952(69)90375-X
P407
P577
1969-10-01T00:00:00Z